Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia

ABSTRACT

Purpose

We describe a case vision-threatening sclerouveitis as a probable adverse drug reaction to ibrutinib.

Methods

Case report.

Results

Ibrutinib is an inhibitor of Bruton's kinase which has shown success in the treatment of hematological malignancies such as chronic lymphocytic leukemia. Despite being generally well tolerated, recent studies have implicated ibrutinib in several adverse events affecting organs such as the heart, intestines, and the eyes. We present the case of a patient who developed severe sclerouveitis after approximately one year of ibrutinib therapy, and suggest this is a probable adverse drug reaction associated with ibrutinib in accordance with the Naranjo algorithm, highlighting the importance of prompt management of ocular symptoms in these patients.

KEYWORDS:

• Uveitis
• immunotherapy
• chronic lymphoid leukemia
• adverse events

Declaration of interest

The authors do not have any conflicts of interest to disclose and did not receive any funding for this work.

Consent for publication

Consent was obtained from the patient for the publication of this case.

Availability of data and material

All data pertaining to this project are contained in the manuscript.

Authors’ contributions

Mr. Parsa Mehraban Far, Dr. Jacob Rullo and Dr. Todd Urton and Dr. James Farmer prepared the manuscript. Dr. Jacob Rullo and Dr. Todd Urton and Dr. James Farmer cared for the patient.